Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NCCAM on echinacea

This article was originally published in The Tan Sheet

Executive Summary

The National Center for Complementary & Alternative Medicine has revised its website "to correct erroneous statements [NCCAM] had made previously" about a study on low-dose echinacea, the NIH center announces Oct. 12. The American Herbal Products Association suggested in an Oct. 4 letter to NCCAM Director Stephen Straus that the revisions be made (1"The Tan Sheet" Oct. 10, 2005, In Brief). The revisions include the removal of the sentence "what's on the label may not always be what's in the bottle," as well as a statement made by Straus endorsing the echinacea study critics felt was inconclusive. NCCAM also added a disclaimer statement as well as one clarifying the dosage used in the trial. The study appeared in the July 28 New England Journal of Medicine (2"The Tan Sheet" Aug. 1, 2005, p. 13)...

You may also be interested in...



AHPA on NCCAM

"AHPA requests that a statement about the potential for mislabeling of dietary supplements that contain echinacea, and herbal preparations generally, be removed from the NCCAM website, and that inaccurate statements attributed to you by numerous news media about a recent study on echinacea be corrected," AHPA states in an Oct. 4 communication to NCCAM Director Stephen Straus, MD. The letter addresses Straus' comment: "Preparations of echinacea, like any herb, can be variable - what's on the label may not always be what's in the bottle." The second clause is a "gratuitous criticism of the industry," the trade group says. AHPA also asks NCCAM to clarify recent "erroneous" statements the center made to The New York Times and The Los Angeles Times regarding echinacea dosages. AHPA separately requested that FDA correct statements about supplements in the GMP final rule...

Echinacea Ineffective For Cold Prevention, Treatment – NEJM Study

Neither preemptive nor early treatment with echinacea prevents the common cold or reduces the severity of its symptoms, a study published in the July 28 New England Journal of Medicine states

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Topics

UsernamePublicRestriction

Register

PS098759

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel